Curaleaf Q3 2026 Results: Revenue Rises 11% to $353 Million

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

Curaleaf posts record Q3 revenue of $352.7 million, up 11% year over year, with adjusted EBITDA of $77.6 million. Gross margin falls 220 basis points to 48.3%, and the company still reports a $37.4 million net loss from continuing operations.

• Operators: Growth is not protecting margins. Wholesale price compression in Germany and several U.S. markets shows more supply and demand alone do not guarantee stronger returns for producers and distributors.
• Investors: Curaleaf targets about $150 million in full-year operating cash flow and holds $104.9 million in cash. International revenue grew 28%, but margin erosion and the open Aurora bid keep profitability and capital needs in focus.
• Do now: Review your wholesale pricing and gross margin by market against your volume growth, and flag any category where rising sales are coming with falling margin.

Short on time? You’re done. Want the numbers?Keep reading ↓

Curaleaf Holdings (TSX: CURA; OTCQX: CURLF) reported record third-quarter revenue of $352.7 million, an 11% increase year over year, supported by growth in both its U.S. operations and international medical cannabis business.

The company reported adjusted EBITDA of $77.6 million, representing a 22% margin, while posting a net loss attributable to shareholders from continuing operations of $37.4 million.

Revenue increased 3.6% sequentially from $340.1 million in the second quarter. Gross profit reached $170.5 million, although the gross margin declined 220 basis points year over year to 48.3%.

The results illustrate Curaleaf’s continued expansion alongside persistent pressure on profitability in competitive cannabis markets.

International Revenue Reaches $59 Million

Curaleaf’s international operations generated approximately $59 million in quarterly revenue, increasing 28% year over year.

The company identified Germany, the United Kingdom and Poland among its important European markets.

Management also highlighted progress in Spain, where Curaleaf secured registrations for standardized cannabis preparations, and France, where the company is preparing for the development of the medical cannabis market.

International expansion presents opportunities for revenue diversification, but it also exposes Curaleaf to different regulatory systems, supply-chain requirements and pricing conditions.

During the earnings call, management described significant price compression in portions of Germany’s medical cannabis wholesale market.

The pressure illustrates how growing patient demand does not necessarily translate into stronger margins for producers and distributors, particularly as additional suppliers compete for market share.

U.S. Revenue Grows Despite Pricing Pressure

Curaleaf’s domestic business recorded approximately 8% year-over-year growth, marking its third consecutive quarter of annual revenue increases.

The company expanded its Florida retail footprint to 78 dispensaries during the quarter, bringing its nationwide operated and managed store count to 188 as of September 30.

Subsequent openings increased its footprint further.

Management attributed domestic progress to cultivation improvements, product innovation and continued retail demand, although wholesale pricing remained challenging in several markets.

Curaleaf’s gross margin contraction suggests that revenue growth alone has not eliminated the financial effects of competition and operating costs.

Cash Flow and Balance Sheet

Curaleaf generated approximately $22 million in operating cash flow during the third quarter and ended September with $104.9 million in cash and cash equivalents.

The company maintained its target of approximately $150 million in operating cash flow for the full year.

Chairman and CEO Boris Jordan said:

“Solid execution across the business is driving growth, strengthening our competitive position, and advancing our Built for Growth plan.”

He also emphasized the company’s international ambitions and efforts to improve operating efficiency.

Aurora Acquisition Remains an Open Question

The earnings release arrived as Curaleaf continues evaluating its options following Organigram’s agreement to acquire Aurora Cannabis.

Curaleaf previously submitted an acquisition proposal for Aurora and subsequently improved its offer. Organigram’s alternative transaction has received the support of Aurora’s board.

Curaleaf stated that it is evaluating the proposed transaction and its options for continuing to pursue an acquisition.

The bidding contest has brought renewed attention to international supply chains, production capacity and access to regulated medical cannabis markets.

For Curaleaf, the financial considerations extend beyond the acquisition price. Any transaction would need to be assessed against its existing capital requirements, operating performance and international expansion strategy.

Looking Ahead

Curaleaf enters the final quarter of 2026 with growing revenue, an expanding international business and continued investments in cultivation and distribution.

The company must nevertheless contend with declining gross margins, international pricing competition and the financial demands of its global strategy.

Its ability to convert revenue growth into sustained profitability and cash generation will remain an important measure of its progress.

The intersection of cannabis finance, federal regulation and international market development will also be central to the IgniteIt Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where investors, operators and policymakers will examine the forces shaping the industry’s next phase.